Showing results (1831-1840 of 1,970) with videos related to
Sort By:
Pageof 197
The British Journal of Dermatology|December 25, 2016
Painful skin lesions and squamous cell carcinoma predict overall mortality risk in organ transplant recipients: a cohort studyC C Oh, G F L Hofbauer, A L Serra, et al.Prostate Cancer and Prostatic Diseases|March 22, 2021
The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world populationH M Westgeest, M C P Kuppen, A J M van den Eertwegh, et al.JAMA Oncology|February 10, 2022
Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical TrialNicholas J Vogelzang, Tomasz M Beer, Winald Gerritsen, et al.Nature Chemical Biology|May 26, 2015
Prolonged and tunable residence time using reversible covalent kinase inhibitorsJ Michael Bradshaw, Jesse M McFarland, Ville O Paavilainen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate CancerTomasz M Beer, Eugene D Kwon, Charles G Drake, et al.Breast Cancer Research and Treatment|July 15, 2019
Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriersBernadette A M Heemskerk-Gerritsen, Agnes Jager, Linetta B Koppert, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2025
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 TrialDaniel P Petrylak, Raffaele Ratta, Nobuaki Matsubara, et al.Prostate Cancer and Prostatic Diseases|July 8, 2022
Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapyMaarten J van der Doelen, Irma M Oving, Dirk N J Wyndaele, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 29, 2024
The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of 223Ra Therapy in Metastatic Castration-Resistant Prostate Cancer PatientsDianne Bosch, Kim J M van der Velden, Irma M Oving, et al.ACS Nano|October 17, 2013
Gold nanocrystal labeling allows low-density lipoprotein imaging from the subcellular to macroscopic levelIris E Allijn, Wei Leong, Jun Tang, et al.Pageof 197